Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

365

HTML

2776

Figures (1-1)

Tables (1-4)

Sum=3143

Jan 28, 2009 (publication date) through Feb 11, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Gastroenterol. Jan 28, 2009; 15(4): 449-456
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449

Figure 1 Kaplan Meier survival estimates by treatment group. A: Progression-free survival; B: overall survival. Bev: bevacizumab.

Citation: Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456
URL: https://www.wjgnet.com/1007-9327/full/v15/i4/449.htm
DOI: https://dx.doi.org/10.3748/wjg.15.449